Endoscopic Third Ventriculostomy vs. Ventriculoperitoneal Shunt in Idiopathic Normal Pressure Hydrocephalus (ENDOVEST)
Key facts
- Who runs it
- University Hospital, Basel, Switzerland
- Where
- Switzerland1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 150 people, planned
- Started
- 17 Jan 2025
- Expected to end
- 1 Jul 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- Endoscopic third ventriculostomy (ETV)
- Ventriculoperitoneal shunt (VPS)
- Record updated
- 3 February 2025
Who can take part
- Age
- 40 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- >40 years of age
- Symptom duration ≥3 months, <24 months
- No antecedent head trauma, ICH, meningitis, or other cause of secondary hydrocephalus
- MUST show gait/balance disturbance, PLUS cognition impairment AND/OR urinary dysfunction
- Ventricular enlargement (Evans Index > 0.3) not attributable to cerebral atrophy or congenital enlargement
- No macroscopic obstruction to cerebrospinal fluid (CSF) flow Spinal Tap-Test
- Opening pressure (on lateral decubitus): <24cmH2O
- Clinical improvement in at least one of the main symptoms after 40-50ml withdrawal of CSF
Who cannot take part
- Previous cranial neurosurgical interventions
- Other neurologic, psychiatric or general medical condition which is sufficient to explain the presenting symptoms
- Other associated dementia syndromes
- ≤40 years of age
- No informed consent
- Incapacity to walk
- Pregnancy and breastfeeding women
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of this single-center, two-arm, open-labeled, randomized controlled clinical study is to compare two surgical interventions, endoscopic third ventriculostomy and ventriculoperitoneal shunt, in treating idiopathic normal pressure hydrocephalus in terms of clinical improvement.
The 2 groups in the trial
- Endoscopic third ventriculostomy (ETV) groupTreatment being tested
The investigational group undergoes endoscopic third ventriculostomy (ETV) for the treatment of idiopathic normal pressure hydrocephalus (iNPH).
Treatment: Endoscopic third ventriculostomy (ETV)
- Ventriculoperitoneal shunt (VPS) groupOther group
The control group undergoes ventriculoperitoneal shunt (VPS) implantation for the treatment of iNPH.
Treatment: Ventriculoperitoneal shunt (VPS)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Endoscopic Third Ventriculostomy Compared to Ventriculoperitoneal Shunt as Treatment for Idiopathic Normal Pressure Hydrocephalus (ENDOVEST): A Randomized Trial
- Record updated
- 3 February 2025